Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Tam on the Combination of Ibrutinib Plus Venetoclax in Mantle Cell Lymphoma

Constantine S. Tam, MD
Published: Wednesday, Jun 14, 2017



Constantine S. Tam, MD, associate professor, Peter MacCullum Cancer Centre, discusses the phase II and phase III studies investigating the combination of ibrutinib (Imbruvica) plus venetoclax (Venclexta) for patients with mantle cell lymphoma (MCL).

The results from the phase II study demonstrate the combination is tolerable and there were no unexpected toxicities, explains Tam. The complete remission rate was 63% and 75% of patients were minimal residual disease-negative.

The phase III study is ongoing, continuing to investigate the combination compared with ibrutinib alone, states Tam.
 


Constantine S. Tam, MD, associate professor, Peter MacCullum Cancer Centre, discusses the phase II and phase III studies investigating the combination of ibrutinib (Imbruvica) plus venetoclax (Venclexta) for patients with mantle cell lymphoma (MCL).

The results from the phase II study demonstrate the combination is tolerable and there were no unexpected toxicities, explains Tam. The complete remission rate was 63% and 75% of patients were minimal residual disease-negative.

The phase III study is ongoing, continuing to investigate the combination compared with ibrutinib alone, states Tam.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x